{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T21:42:22Z","timestamp":1775511742609,"version":"3.50.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,11,22]],"date-time":"2018-11-22T00:00:00Z","timestamp":1542844800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s40272-018-0319-8","type":"journal-article","created":{"date-parts":[[2018,11,21]],"date-time":"2018-11-21T21:07:11Z","timestamp":1542834431000},"page":"593-600","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Dasatinib: A Review in Pediatric Chronic Myeloid Leukemia"],"prefix":"10.1007","volume":"20","author":[{"given":"Emma H.","family":"McCafferty","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sohita","family":"Dhillon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma D.","family":"Deeks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,11,22]]},"reference":[{"issue":"Suppl 4","key":"319_CR1","doi-asserted-by":"publisher","first-page":"iv41","DOI":"10.1093\/annonc\/mdx219","volume":"28","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Saussele S, Rosti G, et al. Chronic myeloid leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(Suppl 4):iv41\u201351.","journal-title":"Ann Oncol."},{"issue":"8","key":"319_CR2","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1182\/blood-2008-03-144790","volume":"113","author":"A Quint\u00e1s-Cardama","year":"2009","unstructured":"Quint\u00e1s-Cardama A, Cortes J. Molecular biology of bcr-abl1\u2013positive chronic myeloid leukemia. Blood. 2009;113(8):1619\u201330.","journal-title":"Blood."},{"issue":"2","key":"319_CR3","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s00277-015-2314-2","volume":"94","author":"M H\u00f6glund","year":"2015","unstructured":"H\u00f6glund M, Sandin F, Simonsson B. Epidemiology of chronic myeloid leukaemia: an update. Ann Hematol. 2015;94(2):241\u20137.","journal-title":"Ann Hematol."},{"issue":"1","key":"319_CR4","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1182\/asheducation-2010.1.368","volume":"2010","author":"M Suttorp","year":"2010","unstructured":"Suttorp M, Millot F. Treatment of pediatric chronic myeloid leukemia in the year 2010: use of tyrosine kinase inhibitors and stem-cell transplantation. Hematol Am Soc Hematol Educ Program. 2010;2010(1):368\u201376.","journal-title":"Hematol Am Soc Hematol Educ Program."},{"key":"319_CR5","unstructured":"SEER. Cancer stat facts: leukemia - chronic myeloid leukemia (CML). 2018. \n                    https:\/\/www.seer.cancer.gov\/\n                    \n                  . Accessed 7 Sep 2018."},{"issue":"1","key":"319_CR6","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1542\/peds.2004-2473","volume":"116","author":"F Millot","year":"2005","unstructured":"Millot F, Traore P, Guilhot J, et al. Clinical and biological features at diagnosis in 40 children with chronic myeloid leukemia. Pediatrics. 2005;116(1):140\u20133.","journal-title":"Pediatrics."},{"key":"319_CR7","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines): chronic myelogenous leukemia (version 1.2018). 2018. \n                    https:\/\/www.nccn.org\/\n                    \n                  . Accessed 7 Sep 2018."},{"issue":"6","key":"319_CR8","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872\u201384.","journal-title":"Blood."},{"key":"319_CR9","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.phrs.2015.10.021","volume":"103","author":"R Roskoski Jr","year":"2016","unstructured":"Roskoski R Jr. Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes. Pharmacol Res. 2016;103:26\u201348.","journal-title":"Pharmacol Res."},{"key":"319_CR10","unstructured":"Bristol-Myers Squibb Company. Sprycel\u00ae (dasatinib): US prescribing information. 2006. \n                    http:\/\/www.packageinserts.bms.com\/pi\/pi_sprycel.pdf\n                    \n                  . Accessed 11 Sep 2018."},{"key":"319_CR11","unstructured":"European Medicines Agency. Dasatinib (Sprycel): EU summary of product characteristics. 2018. \n                    http:\/\/www.ema.europa.eu\/docs\/\n                    \n                  . Accessed 5 Sep 2018."},{"issue":"27","key":"319_CR12","doi-asserted-by":"publisher","first-page":"6658","DOI":"10.1021\/jm049486a","volume":"47","author":"LJ Lombardo","year":"2004","unstructured":"Lombardo LJ, Lee FY, Chen P, et al. Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem. 2004;47(27):6658\u201361.","journal-title":"J Med Chem."},{"issue":"11","key":"319_CR13","doi-asserted-by":"publisher","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","volume":"65","author":"T O\u2019Hare","year":"2005","unstructured":"O\u2019Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005;65(11):4500\u20135.","journal-title":"Cancer Res."},{"issue":"11","key":"319_CR14","doi-asserted-by":"publisher","first-page":"5790","DOI":"10.1158\/0008-5472.CAN-05-4187","volume":"66","author":"JS Tokarski","year":"2006","unstructured":"Tokarski JS, Newitt JA, Chang CY, et al. The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res. 2006;66(11):5790\u20137.","journal-title":"Cancer Res."},{"issue":"26","key":"319_CR15","doi-asserted-by":"publisher","first-page":"18292","DOI":"10.1074\/jbc.M801337200","volume":"283","author":"N Vajpai","year":"2008","unstructured":"Vajpai N, Strauss A, Fendrich G, et al. Solution conformations and dynamics of ABL kinase inhibitor complexes determined by NMR substantiate the different binding modes of imatinib\/nilotinib and dasatinib. J Biol Chem. 2008;283(26):18292\u2013302.","journal-title":"J Biol Chem."},{"issue":"5\u20136","key":"319_CR16","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1177\/1947601912462126","volume":"3","author":"EP Reddy","year":"2012","unstructured":"Reddy EP, Aggarwal AK. The ins and outs of bcr-abl inhibition. Genes Cancer. 2012;3(5\u20136):447\u201354.","journal-title":"Genes Cancer."},{"issue":"5682","key":"319_CR17","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1126\/science.1099480","volume":"305","author":"NP Shah","year":"2004","unstructured":"Shah NP, Tran C, Lee FY, et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004;305(5682):399\u2013401.","journal-title":"Science."},{"issue":"13","key":"319_CR18","doi-asserted-by":"publisher","first-page":"4839","DOI":"10.1182\/blood-2008-04-149948","volume":"112","author":"E Jabbour","year":"2008","unstructured":"Jabbour E, Kantarjian HM, Jones D, et al. Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. Blood. 2008;112(13):4839\u201342.","journal-title":"Blood."},{"issue":"3","key":"319_CR19","doi-asserted-by":"publisher","first-page":"401","DOI":"10.3324\/haematol.10822","volume":"92","author":"S Soverini","year":"2007","unstructured":"Soverini S, Colarossi S, Gnani A, et al. Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. Haematologica. 2007;92(3):401\u20134.","journal-title":"Haematologica."},{"issue":"3","key":"319_CR20","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1200\/JCO.2008.19.8853","volume":"27","author":"S Redaelli","year":"2009","unstructured":"Redaelli S, Piazza R, Rostagno R, et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR\/ABL mutants. J Clin Oncol. 2009;27(3):469\u201371.","journal-title":"J Clin Oncol."},{"issue":"6","key":"319_CR21","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/S0092-8674(03)00190-9","volume":"112","author":"M Azam","year":"2003","unstructured":"Azam M, Latek RR, Daley GQ. Mechanisms of autoinhibition and STI-571\/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell. 2003;112(6):831\u201343.","journal-title":"Cell."},{"issue":"2","key":"319_CR22","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","volume":"2","author":"NP Shah","year":"2002","unstructured":"Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2002;2(2):117\u201325.","journal-title":"Cancer Cell."},{"issue":"2","key":"319_CR23","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","volume":"7","author":"E Weisberg","year":"2005","unstructured":"Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005;7(2):129\u201341.","journal-title":"Cancer Cell."},{"issue":"4","key":"319_CR24","doi-asserted-by":"publisher","first-page":"e34914","DOI":"10.1371\/journal.pone.0034914","volume":"7","author":"A Garcia-Gomez","year":"2012","unstructured":"Garcia-Gomez A, Ocio EM, Crusoe E, et al. Dasatinib as a bone-modifying agent: anabolic and anti-resorptive effects. PLoS One. 2012;7(4):e34914.","journal-title":"PLoS One."},{"issue":"5","key":"319_CR25","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/leu.2008.356","volume":"23","author":"K Vandyke","year":"2009","unstructured":"Vandyke K, Dewar AL, Farrugia AN, et al. Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis. Leukemia. 2009;23(5):994\u20137.","journal-title":"Leukemia."},{"issue":"3","key":"319_CR26","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/leu.2008.237","volume":"23","author":"N Brownlow","year":"2009","unstructured":"Brownlow N, Mol C, Hayford C, et al. Dasatinib is a potent inhibitor of tumour-associated macrophages, osteoclasts and the FMS receptor. Leukemia. 2009;23(3):590\u20134.","journal-title":"Leukemia."},{"issue":"8","key":"319_CR27","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1002\/jbmr.85","volume":"25","author":"K Vandyke","year":"2010","unstructured":"Vandyke K, Dewar AL, Diamond P, et al. The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivo. J Bone Miner Res. 2010;25(8):1759\u201370.","journal-title":"J Bone Miner Res."},{"issue":"9","key":"319_CR28","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1002\/cncr.29933","volume":"122","author":"CA Schiffer","year":"2016","unstructured":"Schiffer CA, Cortes JE, Hochhaus A, et al. Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: effects on response and toxicity. Cancer. 2016;122(9):1398\u2013407.","journal-title":"Cancer."},{"issue":"1","key":"319_CR29","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3324\/haematol.13151","volume":"94","author":"DH Kim","year":"2009","unstructured":"Kim DH, Kamel-Reid S, Chang H, et al. Natural killer or natural killer\/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia. Haematologica. 2009;94(1):135\u20139.","journal-title":"Haematologica."},{"key":"319_CR30","unstructured":"European Medicines Agency. Assessment report: Sprycel. 2018. \n                    http:\/\/www.ema.europa.eu\/ema\/\n                    \n                  . Accessed 5 Sep 2018."},{"issue":"24","key":"319_CR31","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","volume":"362","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362(24):2260\u201370.","journal-title":"N Engl J Med."},{"issue":"1","key":"319_CR32","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s40265-016-0677-x","volume":"77","author":"GM Keating","year":"2017","unstructured":"Keating GM. Dasatinib: a review in chronic myeloid leukaemia and Ph+ acute lymphoblastic leukaemia. Drugs. 2017;77(1):85\u201396.","journal-title":"Drugs."},{"issue":"19","key":"319_CR33","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1200\/JCO.2012.46.8280","volume":"31","author":"CM Zwaan","year":"2013","unstructured":"Zwaan CM, Rizzari C, Mechinaud F, et al. Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium. J Clin Oncol. 2013;31(19):2460\u20138.","journal-title":"J Clin Oncol."},{"issue":"4","key":"319_CR34","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1182\/blood-2008-02-140665","volume":"112","author":"K Porkka","year":"2008","unstructured":"Porkka K, Koskenvesa P, Lundan T, et al. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood. 2008;112(4):1005\u201312.","journal-title":"Blood."},{"issue":"4","key":"319_CR35","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1805131","volume":"379","author":"MR Migden","year":"2018","unstructured":"Migden MR, Rischin D, Schmults CD, et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med. 2018;379(4):341\u201351.","journal-title":"N Engl J Med."},{"issue":"7","key":"319_CR36","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1124\/dmd.107.018267","volume":"36","author":"LJ Christopher","year":"2008","unstructured":"Christopher LJ, Cui D, Wu C, et al. Metabolism and disposition of dasatinib after oral administration to humans. Drug Metab Dispos. 2008;36(7):1357\u201364.","journal-title":"Drug Metab Dispos."},{"issue":"13","key":"319_CR37","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1200\/JCO.2017.75.9597","volume":"36","author":"L Gore","year":"2018","unstructured":"Gore L, Kearns PR, de Martino ML, et al. Dasatinib in pediatric patients with chronic myeloid leukemia in chronic phase: results from a phase II trial. J Clin Oncol. 2018;36(13):1330\u20138.","journal-title":"J Clin Oncol."},{"issue":"20","key":"319_CR38","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","volume":"34","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, Saglio G, Kantarjian HM, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34(20):2333\u201340.","journal-title":"J Clin Oncol."},{"issue":"9","key":"319_CR39","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1002\/ajh.24423","volume":"91","author":"NP Shah","year":"2016","unstructured":"Shah NP, Rousselot P, Schiffer C, et al. Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034. Am J Hematol. 2016;91(9):869\u201374.","journal-title":"Am J Hematol."},{"issue":"1","key":"319_CR40","first-page":"100","volume":"56","author":"E Buchdunger","year":"1996","unstructured":"Buchdunger E, Zimmermann J, Mett H, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 1996;56(1):100\u20134.","journal-title":"Cancer Res."},{"issue":"15","key":"319_CR41","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1182\/blood-2014-05-578567","volume":"124","author":"F Millot","year":"2014","unstructured":"Millot F, Guilhot J, Baruchel A, et al. Impact of early molecular response in children with chronic myeloid leukemia treated in the French Glivec phase 4 study. Blood. 2014;124(15):2408\u201310.","journal-title":"Blood."},{"issue":"4","key":"319_CR42","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1182\/blood-2015-06-648667","volume":"127","author":"N Hijiya","year":"2016","unstructured":"Hijiya N, Schultz KR, Metzler M, et al. Pediatric chronic myeloid leukemia is a unique disease that requires a different approach. Blood. 2016;127(4):392\u20139.","journal-title":"Blood."},{"issue":"11","key":"319_CR43","doi-asserted-by":"publisher","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","volume":"107","author":"M Copland","year":"2006","unstructured":"Copland M, Hamilton A, Elrick LJ, et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood. 2006;107(11):4532\u20139.","journal-title":"Blood."},{"issue":"1","key":"319_CR44","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1182\/blood.V99.1.319","volume":"99","author":"SM Graham","year":"2002","unstructured":"Graham SM, J\u00f8rgensen HG, Allan E, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood. 2002;99(1):319\u201325.","journal-title":"Blood."},{"issue":"9","key":"319_CR45","doi-asserted-by":"publisher","first-page":"4016","DOI":"10.1182\/blood-2006-11-057521","volume":"109","author":"HG J\u00f8rgensen","year":"2007","unstructured":"J\u00f8rgensen HG, Allan EK, Jordanides NE, et al. Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34\u2009+\u2009CML cells. Blood. 2007;109(9):4016\u20139.","journal-title":"Blood."},{"issue":"6","key":"319_CR46","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","volume":"108","author":"M Baccarani","year":"2006","unstructured":"Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108(6):1809\u201320.","journal-title":"Blood."}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40272-018-0319-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-018-0319-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-018-0319-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T19:20:53Z","timestamp":1574364053000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40272-018-0319-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,22]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["319"],"URL":"https:\/\/doi.org\/10.1007\/s40272-018-0319-8","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,22]]},"assertion":[{"value":"22 November 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Emma McCafferty, Sohita Dhillon and Emma Deeks are salaried employees of Adis\/Springer, are responsible for the article content and declare no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}